单倍体与无关供者异基因移植治疗首次完全缓解急性淋巴细胞白血病的比较:EBMT的ALWP报告
该研究分析了2007至2016年间1234例接受异基因造血干细胞移植的成人急性淋巴细胞白血病首次完全缓解(CR1)患者,比较单倍体(136例)、10/10相合无关供者(MUD,809例)和9/10不合无关供者(MMUD,289例)的结局。单因素和多因素分析均显示,单倍体移植的总生存、无白血病生存、复发、非复发死亡及急慢性GVHD与MUD或MMUD移植相当。因此,单倍体移植可作为缺乏相合同胞供者患者的临床相关选择。
要点
- 单倍体移植的OS、LFS、RI、NRM及GVHD与MUD或MMUD移植无显著差异。
- 多因素分析中,与单倍体相比,MUD和MMUD的LFS、OS、RI、NRM及GVHD风险比均无统计学意义。
- 缺乏相合同胞供者的ALL患者可考虑单倍体移植作为替代方案。
核心结论
- 成人ALL首次完全缓解接受单倍体移植的结局与MUD或MMUD移植相当,单倍体移植是缺乏相合同胞供者时的临床相关选择。
研究设计与样本
- 回顾性分析2007至2016年1234例成人ALL首次完全缓解(CR1)接受异基因造血干细胞移植的患者,比较单倍体(136例)、MUD 10/10(809例)和MMUD 9/10(289例)的结局。
主要发现
- 单因素分析显示单倍体、MUD和MMUD在OS、LFS、RI、NRM、急性GVHD和慢性GVHD方面结局相似。
- 多因素分析中,与单倍体相比,MUD的LFS、OS、RI、NRM、急性GVHD和慢性GVHD的风险比分别为1.1(p=0.7)、0.9(p=0.4)、1.35(p=0.2)、0.7(p=0.2)、1.1(p=0.8)和0.8(p=0.2)。
- 多因素分析中,与单倍体相比,MMUD的LFS、OS、RI、NRM、急性GVHD和慢性GVHD的风险比分别为1.1(p=0.8)、1.0(p=1.0)、1.2(p=0.3)、0.8(p=0.4)、1.2(p=0.3)和0.9(p=0.6)。
临床怎么用
- 对于缺乏HLA相合同胞供者的成人ALL首次完全缓解患者,可考虑单倍体异基因造血干细胞移植作为临床相关选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Unmanipulated haploidentical allogeneic stem cell transplantation (Allo-SCT) has become an attractive alternative for patients lacking HLA-matched sibling or unrelated donors. However, data of outcome in ALL is still scarce. The outcomes of 1234 adult patients with ALL in first complete remission (CR1) who underwent Allo-SCT between 2007 and 2016 were analyzed. Comparison was done between haploidentical donor (Haplo) (136 patients), matched unrelated donor (MUD 10/10) (809 patients), and mismatched unrelated donor (MMUD 9/10) (289 patients). Univariate analysis showed similar outcomes in Haplo, MUD, and MMUD, including OS, LFS, RI, NRM, AGVHD, and CGVHD. In multivariate analysis, Haplo was not associated with worse outcomes compared to MUD 10/10 and MMUD 9/10. Indeed, compared to Haplo, the hazard ratio (HR) for LFS, OS, RI, NRM, AGVHD, and CGVHD were 1.1 (p = 0.7), 0.9 (p = 0.4), 1.35 (p = 0.2), 0.7 (p = 0.2), 1.1 (p = 0.8), and 0.8 (p = 0.2) for MUD, respectively, and 1.1 (p = 0.8), 1.0 (p = 1.0), 1.2 (p = 0.3), 0.8 (p = 0.4), 1.2 (p = 0.3), and 0.9 (p = 0.6) for MMUD, respectively. In conclusion, outcomes of adult patients with ALL in CR1 receiving Haplo Allo-SCT are comparable to MUD or MMUD transplants. Haplo should be considered as a clinically relevant option for patients lacking a matched sibling donor.
引用
- Shem-Tov N, Peczynski C, Labopin M, et al. Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT. Leukemia. 2019. PMID: 31427719. doi:10.1038/s41375-019-0544-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。